This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Signs Point to MAP Pharma Drug Rejection

MOUNTAIN VIEW, Calif. ( TheStreet) -- No official word yet but U.S. regulators have more than likely rejected an inhaled migraine drug from MAP Pharmaceuticals (MAPP).

How do I know this? In response to a question about the regulatory status of Levadex, an FDA spokesperson told me via email, "The company MAP Pharma should be able to provide you with an update on Levadex."

FDA does not publicly announce drug rejections, therefore, the most likely scenario is that regulators told MAP Pharma earlier today that Levadex cannot be approved. It's up to MAP Pharma to disclose the Levadex rejection.

"The company will update publicly when ready," said a MAPP Pharma spokesperson via an email sent at 2 pm EDT. More than two hours later, we're still waiting for MAP Pharma to say something about Levadex. If the drug were approved, MAP Pharma would be quick with an announcement.

MAP Pharma shares were up 7% to $17.14 Monday before being halted just before 2 pm EDT. The stock's market value has increased 30% this year on investor confidence in Levadex's approval. A chorus of sell-side analysts predicting the same certainly helped.

MAP's stock gains will disappear if/when the FDA's rejection of Levadex is confirmed. How far the stock falls will likely depend on the specific concerns raised by FDA and what the company needs to do in order to resubmit the drug for approval again.

MAP Pharma has about $3.30 per share cash based off its first-quarter burn rate.

Levadex is an inhaled formulation of DHE, a drug already used in intravenous and nasal spray formulations to treat migraines. MAP Pharma developed a simple device that allows patients suffering from acute migraines to inhale the drug into their lungs, thereby accelerating pain relief.

Had Levadex been approved, Allergan (AGN) was set to market the drug to pain specialists and neurologists under a marketing partnership signed with MAP Pharma. Nektar Therapeutics> (NKTR) was to receive royalties on sales of the drug.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,055.87 -116.81 -0.68%
S&P 500 1,982.77 -11.52 -0.58%
NASDAQ 4,508.6880 -19.0010 -0.42%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs